| Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells O Firuzi, PP Che, B El Hassouni, M Buijs, S Coppola, M Löhr, N Funel, ... Cancers 11 (5), 638, 2019 | 75 | 2019 |
| Imidazo [2, 1-b][1, 3, 4] thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells S Cascioferro, GL Petri, B Parrino, D Carbone, N Funel, C Bergonzini, ... European journal of medicinal chemistry 189, 112088, 2020 | 72 | 2020 |
| Detection and localization of early-and late-stage cancers using platelet RNA S GJG, M Arkani, E Post, M Antunes-Ferreira, S D’Ambrosi, DCL Vessies, ... Cancer Cell 40 (9), 999-1009. e6, 2022 | 64 | 2022 |
| Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets TYS Le Large, G Mantini, LL Meijer, TV Pham, N Funel, NCT van Grieken, ... JCI insight 5 (15), e138290, 2020 | 48 | 2020 |
| Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds G Li Petri, B El Hassouni, R Sciarrillo, N Funel, G Mantini, ... British Journal of Cancer 123 (4), 644-656, 2020 | 42 | 2020 |
| Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma TYS Le Large, MF Bijlsma, B El Hassouni, G Mantini, T Lagerweij, ... Journal of Experimental & Clinical Cancer Research 40, 1-12, 2021 | 36 | 2021 |
| Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors C Granchi, G Bononi, R Ferrisi, E Gori, G Mantini, S Glasmacher, G Poli, ... European journal of medicinal chemistry 209, 112857, 2021 | 35 | 2021 |
| To combine or not combine: drug interactions and tools for their analysis. Reflections from the EORTC-PAMM course on preclinical and early-phase clinical pharmacology B El Hassouni, G Mantini, GL Petri, M Capula, L Boyd, HNW Weinstein, ... Anticancer Research 39 (7), 3303-3309, 2019 | 34 | 2019 |
| “Open Sesame?”: Biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and … O Randazzo, F Papini, G Mantini, A Gregori, B Parrino, DSK Liu, ... Cancers 12 (11), 3206, 2020 | 31 | 2020 |
| Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers G Mantini, AM Vallés, TYS Le Large, M Capula, N Funel, TV Pham, ... Cellular oncology 43, 1147-1159, 2020 | 30 | 2020 |
| Computational analysis of phosphoproteomics data in multi‐omics cancer studies G Mantini, TV Pham, SR Piersma, CR Jimenez Proteomics 21 (3-4), 1900312, 2021 | 28 | 2021 |
| New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism M Capula, G Mantini, N Funel, E Giovannetti Expert Review of Clinical Pharmacology 12 (12), 1081-1090, 2019 | 26 | 2019 |
| Omics analysis of educated platelets in cancer and benign disease of the pancreas G Mantini, LL Meijer, I Glogovitis, SGJG In ‘t Veld, R Paleckyte, M Capula, ... Cancers 13 (1), 66, 2020 | 23 | 2020 |
| CX-5461 inhibits pancreatic ductal adenocarcinoma cell growth, migration and induces DNA damage B El Hassouni, G Mantini, B Immordino, GJ Peters, E Giovannetti Molecules 24 (24), 4445, 2019 | 21 | 2019 |
| Prognostic significance of integrin subunit alpha 2 (ITGA2) and role of mechanical cues in resistance to gemcitabine in pancreatic ductal adenocarcinoma (PDAC) A Gregori, C Bergonzini, M Capula, G Mantini, F Khojasteh-Leylakoohi, ... Cancers 15 (3), 628, 2023 | 18 | 2023 |
| ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells C Bergonzini, A Gregori, TMS Hagens, VE van der Noord, B van de Water, ... Journal of Experimental & Clinical Cancer Research 43 (1), 4, 2024 | 14 | 2024 |
| Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma A Vallés-Martí, G Mantini, P Manoukian, C Waasdorp, AF Sarasqueta, ... Cell Reports 42 (6), 2023 | 13 | 2023 |
| Uridine cytidine kinase 2 as a potential biomarker for treatment with RX-3117 in pancreatic cancer B El Hassouni, J Infante, G Mantini, C Ricci, N Funel, E Giovannetti, ... Anticancer Research 39 (7), 3609-3614, 2019 | 11 | 2019 |
| Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma IGP Supadmanaba, G Mantini, O Randazzo, M Capula, IB Muller, ... Epigenetics 17 (4), 381-404, 2022 | 10 | 2022 |
| Exploring splicing modulation as an innovative approach to combat pancreatic cancer: SF3B1 emerges as a prognostic indicator and therapeutic target R Sciarrillo, F Terrana, A Comandatore, IGP Supadmanaba, B Wang, ... International Journal of Biological Sciences 20 (8), 3173, 2024 | 2 | 2024 |
